Citations

Showing 10 of 108104 citations.

The Brief Case: The Unexpected Souvenir
Asbury, Kara , Seville, Maria Teresa , Pritt, Bobbi S. , Scotch, Allison H., Kelemen, Katalin, Pritt, Bobbi, Scotch, Allison, Grys, Thomas E. , Pritt, Bobbi S , Rosenthal, Allison

Mayo Clinic

Journal of Clinical Microbiology | August 24, 2018 | Volume: 56 | Issue: 9 | Pages: No page available

10.1128/jcm.01387-17 | PMID 30150292 Get It

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials
Bottomley, Andrew , Pe, Madeline , Sloan, Jeff A. , Basch, Ethan , Bonnetain, Franck, Calvert, Melanie , Campbell, Alicyn, Cleeland, Charles S. , Cocks, Kim , Collette, Laurence , Dueck, Amylou C. , Flechtner, Hans‐Henning , Gotay, Carolyn , Greimel, Eva , Griebsch, Ingolf , Grøenvold, Mogens , Hamel, Jean-François, King, Madeleine , Koller, Michael , Malone, Daniel C. , Martinelli, Francesca , Moinpour, Carol M. , Musoro, Jammbe , O’Connor, Daniel , Oliver, Kathy , Piault‐Louis, Elisabeth, Piccart, Martine , Pimentel, Francisco , Quinten, Chantal , Reijneveld, Jaap C. , Soltys, Katherine M, Sridhara, Rajeshwari , Taphoorn, Martin , Velikova, Galina , Coens, Corneel , Sloan, Jeff, Flechtner, Hans-Henning , Dueck, A. C. , Basch, Ethan , Devlin, Nancy J. , Kluetz, Paul Gustav , Mitchell, Sandra A , Schürmann, Christoph, Smith, Ashley Wilder

Mayo Clinic

Clinical Trials | August 24, 2018 | Volume: 15 | Issue: 6 | Pages: 624-630

10.1177/1740774518795637 | PMID 30141714 Get It

Background There is currently a lack of consensus on how health-related quality of life and other patient-reported outcome measures in cancer randomized clinical trials are analyzed and interpreted. This makes it difficult to compare results across randomized controlled trials (RCTs) synthesize scientific research, and use that evidence to inform product labeling, clinical guidelines, and health policy. The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data for Cancer Clinical Trials (SISAQOL) Consortium aims to develop guidelines and recommendations to standardize analyses of patient-reported outcome data in cancer RCTs. Methods and Results Members from the SISAQOL Consortium met in January 2017 to discuss relevant issues. Data from systematic reviews of the current state of published research in patient-reported outcomes in cancer RCTs indicated a lack of clear reporting of research hypothesis and analytic strategies, and inconsistency in definitions of terms, including “missing data,”“health-related quality of life,” and “patient-reported outcome.” Based on the meeting proceedings, the Consortium will focus on three key priorities in the coming year: developing a taxonomy of research objectives, identifying appropriate statistical methods to analyze patient-reported outcome data, and determining best practices to evaluate and deal with missing data. Conclusion The quality of the Consortium guidelines and recommendations are informed and enhanced by the broad Consortium membership which includes regulators, patients, clinicians, and academics.
Osteochondritis Dissecans of the Knee: Short-Term Outcomes of a Hybrid Technique to Restore a Partially Salvageable Progeny Fragment
Melugin, Heath P. , Desai, Vishal , Levy, Bruce A. , Tanaka, Yoshinari , Horibe, Shuji , Krych, Aaron J. , Desai, Vishal S. , Krych, Aaron J , Nakamura, Norimasa

Mayo Clinic

CARTILAGE | August 24, 2018 | Volume: 11 | Issue: 3 | Pages: 300-308

10.1177/1947603518796132 | PMID 30141694 Get It

Objective This retrospective case series describes a hybrid fixation technique and determines the clinical outcomes, knee function, and activity level of patients at short-term follow-up. Design Seventeen patients (18 knees) with unstable osteochondritis dissecans (OCD) lesions involving the knee were treated with a hybrid fixation technique in which the salvageable fragment was fixed and osteochondral autograft transplantation system (OATS) was used for the unsalvageable fragment. Thirteen lesions involved the medial femoral condyle, 4 involved the lateral femoral condyle, and 1 involved the patella. Mean patient age was 17 years (range 12-28 years). All lesions were International Cartilage Repair Society (ICRS) grade III or IV. The patients were prospectively followed postoperatively. Outcome measures included the International Knee Documentation Committee (IKDC) score, Knee injury and Osteoarthritis Outcome Score (KOOS), and the Tegner activity scale. Results At mean follow-up of 36 months (range 24-67.2 months), the mean postoperative KOOS scores, given as mean (SD), were as follows: Quality of Life (QoL) 91.1 (17.0), Activities of Daily Living (ADL) 99.5 (1.5), Sport 94.5 (11.2), Pain 97.4 (5.8), and Symptoms 95.9 (6.5). Mean IKDC score was 96.2 (7.0). There was no significant difference between mean preinjury (7.95, SD = 1.1) and mean postoperative (7.45, SD = 1.5) Tegner scores ( P = 0.363). The mean Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score was 87.5 at a mean 7.8 months (range 3-18 months) postoperation. There were no reported complications. Conclusion The results of this case series suggest that patients with partially salvageable OCD lesions involving the knee can have positive short-term outcomes and can expect a low complication rate when treated with a hybrid technique of fixation with osteochondral autograft transfer.
High‐Volume Anesthetic Suboccipital Nerve Blocks for Treatment Refractory Chronic Cluster Headache With Long‐Term Efficacy Data: An Observational Case Series Study
Rozen, Todd D. , Peres, Mário Fernando Prieto , Rozen, Todd D.

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 24, 2018 | Volume: 59 | Issue: 1 | Pages: 56-62

10.1111/head.13394 | PMID 30144049 Get It

Objective To determine the efficacy of high‐volume anesthetic suboccipital nerve blocks (HVSON) for chronic cluster headache (CCH) and to define consistency of response over long‐term use. Background There are studies showing efficacy of greater occipital and suboccipital nerve block injections for CCH and also their possible use as a preventive treatment modality. There are scant data about the long‐term efficacy of repetitive greater occipital and suboccipital nerve injections in CCH. HVSON has not been studied for CH. Methods This was an open label, observational, case series study. Patients with CCH seen at a dedicated headache clinic over a 7‐year time period and injected on at least 2 separate occasions were used for analysis. All were deemed medicinal treatment refractory. HVSON consisted of 9 mL 1% lidocaine and 1 mL triamcinolone 40 mg/mL injected on the side of CH. Results Ten CCH patients were retrospectively studied. Range of mean average response to HVSON (all patients had complete pain freedom) was 1.5–31 weeks (longest: 44 weeks in 2 patients). Only one patient did not respond; 2 patients had 1.5–2 weeks of response; the remainder had at least 4 weeks of response. The mean average duration of effect was 10.3 weeks in the responders. Five patients were injected serially for 2–4 years (30x, 17x, 15x, 10x and 3x, respectively) with a consistent response of 6 weeks, 4 weeks, 12 weeks, 4 weeks, and 31 weeks, respectively, after each injection. Response duration was very reliable per individual patient. All 5 patients felt HVSON was effective as a preventive treatment. Smoking history did not appear to alter treatment response (8/10 were chronic current smokers and 7/8 responded to HVSON). The one patient who received the most injections developed avascular necrosis of the hip; the remainder of the subjects had no adverse events. Conclusion HVSON from this open label study appears to be effective in the preventive treatment of medicinal refractory CCH and shows consistent response over long‐term use with high rates of pain freedom.
Design of a Controlled Trial of Cascade Screening for Hypercholesterolemia: The (CASH) Study
Bailey, Kent R. , Kullo, Iftikhar J.

Mayo Clinic

Journal of Personalized Medicine | August 24, 2018 | Volume: 8 | Issue: 3 | Pages: 27

10.3390/jpm8030027 | PMID 30142941 Get It

To inform guidelines for screening family members of patients with familial hypercholesterolemia (FH), we designed a clinical trial to compare the yield of cascade screening in FH patients with and without an identifiable pathogenic variant. Participants with hypercholesterolemia (Low-density lipoprotein cholesterol (LDL-C) > 155 mg/dL) underwent sequencing of LDLR, APOB, and PCSK9 and genotyping of six single nucleotide polymorphisms associated with LDL-C followed by calculation of a polygenic score for LDL-C. We identified 24 patients with definite FH (pathogenic variant in one of the three FH genes), 76 patients with probable FH (Dutch lipid clinic network (DLCN) score ≥ 6, no pathogenic variant), and 262 patients with possible FH (DLCN score 3–5, no pathogenic variant). We will enroll 50 patients with definite FH by recruiting an additional 26 from the FH Clinic at Mayo and 50 patients each with probable and possible FH, matching on age and sex. Family members of patients with definite FH will undergo testing for the relevant pathogenic variant using saliva kits and family members of those with probable/possible FH will have a lipid profile checked. We will assess the number of new cases detected (defined as presence of a pathogenic variant in the family member of definite FH patient or LDL-C > 155 mg/dL (>130 mg/dL in children) in family members of probable/possible FH patients, and the cost of detecting a new case. The proposed clinical trial will compare the yield and cost of cascade screening for FH patients with/without an identifiable pathogenic variant, and thereby inform guidelines for cascade screening for FH.
Immunoglobulin G4 Sclerosing Cholangitis: An Unusual Cause of Obstructive Jaundice—Case Report and Literature Review
Shrestha, Pragya , Le, Brian , Wagner, Brent J., Pompella, William, Karmacharya, Paras , Karmacharya, Paras

Mayo Clinic

Case Reports in Rheumatology | August 23, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-5

10.1155/2018/9602373 | PMID 30210896 Get It

IgG4-related sclerosing cholangitis (IgG4-SC) is one of the most common extra-pancreatic manifestation of IgG4-related disease (IgG4-RD) and is clinically distinct from primary sclerosing cholangitis (PSC). IgG4-RD is an increasingly recognized immune-mediated fibroinflammatory systemic disease, mostly affecting middle-aged and older male populations that can affect multiple organs. The presence of extra-biliary clinical manifestations of IgG4-RD, such as parotid and lacrimal swelling, lymphadenopathy, autoimmune pancreatitis, and retroperitoneal fibrosis, if present could provide important clues to diagnosis. High serum IgG4 levels, characteristic radiological (e.g., sausage-shaped pancreas or periaortitis) or biopsy findings (high percentage of IgG4+ plasma cells, lymphoplasmacytic infiltrate, storiform fibrosis, or obliterative phlebitis) in the setting of these features is diagnostic of this disease process. However, isolated IgG4-SC might be a diagnostic challenge, and the distinction is important as management of this disorder is vastly different from other causes of cholangitis such as PSC. Systemic corticosteroid therapy is the mainstay of therapy.
The Turnover in Normal Dogs of Prothrombin and Its Fragments; Effect of Induced Intravascular Coagulation
Owen, Charles A., Mann, Kenneth G. , McDuffie, Frederic C.

Mayo Clinic

Thrombosis and Haemostasis | August 23, 2018 | Volume: 42 | Issue: 02 | Pages: 548-555

10.1055/s-0038-1666892 Get It

SummaryWhen 125I-labeled canine prothrombin was given to normal adult dogs intravenously, it was calculated that 240% of the plasma prothrombin crossed the capillary barrier per day, 410% of the interstitial prothrombin returned to the blood stream daily, and 79% of the plasmatic prothrombin was catabolized per day. These data are in close agreement with those observed for bovine prothrombin in calves by Takeda (1970).When derived from normal dog prothrombin, prethrombin-1 is a mixture of 2 polypeptides, one larger than the other, and both present in about equal amounts. The longer peptide, “prethrombin-1-long,” was catabolized twice as fast as prothrombin, and the shorter, “prethrombin-1-short,” 4 times faster. Prothrombin fragment-1 was catabolized by the normal dog still more rapidly.The catabolism of prothrombin was not accelerated in 3 dogs receiving continuous infusions of a thromboplastic emulsion of dog brain. Nor was the level of prothrombin in their plasma remarkably altered.
Association of Preferences for Papillary Thyroid Cancer Treatment With Disease Terminology
Nickel, Brooke , Howard, Kirsten , Brito, Juan P. , Barratt, Alexandra , Moynihan, Ray , McCaffery, Kirsten , Brito, Juan P

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | August 23, 2018 | Volume: 144 | Issue: 10 | Pages: 887

10.1001/jamaoto.2018.1694 | PMID 30140909 Get It

Anesthesiologists’ Overconfidence in Their Perceived Knowledge of Neuromuscular Monitoring and Its Relevance to All Aspects of Medical Practice: An International Survey
Naguib, Mohamed , Brull, Sorin J. , Hunter, Jennifer M. , Kopman, Aaron F., Johnson, Ken B. , Arkes, Hal R. , Fülesdi, Béla , Brull, Sorin J

Mayo Clinic

Anesthesia & Analgesia | August 23, 2018 | Volume: 128 | Issue: 6 | Pages: 1118-1126

10.1213/ane.0000000000003714 | PMID 31094776 Get It

BACKGROUND: In patients who receive a nondepolarizing neuromuscular blocking drug (NMBD) during anesthesia, undetected postoperative residual neuromuscular block is a common occurrence that carries a risk of potentially serious adverse events, particularly postoperative pulmonary complications. There is abundant evidence that residual block can be prevented when real-time (quantitative) neuromuscular monitoring with measurement of the train-of-four ratio is used to guide NMBD administration and reversal. Nevertheless, a significant percentage of anesthesiologists fail to use quantitative devices or even conventional peripheral nerve stimulators routinely. Our hypothesis was that a contributing factor to the nonutilization of neuromuscular monitoring was anesthesiologists’ overconfidence in their knowledge and ability to manage the use of NMBDs without such guidance. METHODS: We conducted an Internet-based multilingual survey among anesthesiologists worldwide. We asked respondents to answer 9 true/false questions related to the use of neuromuscular blocking drugs. Participants were also asked to rate their confidence in the accuracy of each of their answers on a scale of 50% (pure guess) to 100% (certain of answer). RESULTS: Two thousand five hundred sixty persons accessed the website; of these, 1629 anesthesiologists from 80 countries completed the 9-question survey. The respondents correctly answered only 57% of the questions. In contrast, the mean confidence exhibited by the respondents was 84%, which was significantly greater than their accuracy. Of the 1629 respondents, 1496 (92%) were overconfident. CONCLUSIONS: The anesthesiologists surveyed expressed overconfidence in their knowledge and ability to manage the use of NMBDs. This overconfidence may be partially responsible for the failure to adopt routine perioperative neuromuscular monitoring. When clinicians are highly confident in their knowledge about a procedure, they are less likely to modify their clinical practice or seek further guidance on its use.
Reducing the Rate of Minimally Invasive Hysterectomy for Fibroids in Favor of Abdominal Surgery—There Is Always Something Evil in Good Intentions—Reply
Mariani, Andrea , Laughlin-Tommaso, Shannon K., Multinu, Francesco

Mayo Clinic

JAMA Surgery | August 23, 2018 | Volume: 153 | Issue: 11 | Pages: 1063

10.1001/jamasurg.2018.2733 | PMID 30140898 Get It